10-Q · May 7, 2026
Silence Therapeutics reported a first quarter 2026 net loss of $14.96 million, significantly improving from a loss of $28.53 million in the same period last year. Revenue from collaboration with AstraZeneca increased to…
Earnings analysis · 10-Q
SLN earnings analysis
Filed August 10, 2026 · Our reading of the company's report
The latest report
Silence Therapeutics reported $0 of second-quarter revenue and a $0.09 loss per share, but the net loss improved to $12.268 million from $27.354 million year over year as R&D expense fell by $8.4 million. The filing…
Read full summary
Silence Therapeutics reported $0 of second-quarter revenue and a $0.09 loss per share, but the net loss improved to $12.268 million from $27.354 million year over year as R&D expense fell by $8.4 million. The filing provides no quantitative EPS or revenue guidance and does not address the prior $22.0 million-$24.0 million full-year revenue outlook. Ongoing losses and the absence of quarterly revenue remain significant risks, although controls were assessed as effective as of June 30, 2026.
How we read each report
Our analysis across the last few reports.
Our model's reading of each filing, not the share price or the market's reaction. Annual and quarterly reports each occupy one position.
Reported figures
- Earnings per share
- $-0.09
What stood out
-
Revenue remained at $0
Second-quarter revenue was $0, while reported EPS was a loss of $0.09. No segment revenue breakdown was disclosed.
-
Net loss narrowed materially
Net loss narrowed to $12.268 million from $27.354 million in the prior-year period, an improvement of $15.086 million.
-
R&D expense fell $8.4 million
Research and development expense declined by $8.4 million year over year, contributing to the narrower net loss.
-
Disclosure controls deemed effective
Management concluded that disclosure controls and procedures were effective at the reasonable assurance level as of June 30, 2026.
What to watch
-
No quarterly revenue
Revenue was $0 in the quarter, underscoring the company’s dependence on future licensing, collaboration or product-related revenue to fund operations.
-
Continuing operating losses
The company continued to report a net loss of $12.268 million despite the year-over-year improvement from $27.354 million, indicating ongoing operating losses and financing needs.
-
No new risk-factor disclosure
The risk-factor section points investors back to the 2025 Form 10-K and does not identify new or changed risk factors; the filing also states that the company is party to 0 material legal proceedings at this time.
Management's outlook
No numeric EPS guidance was provided. The prior full-year revenue outlook of $22.0 million-$24.0 million was not addressed in the filing/release.
Earlier filings 4
10-K · March 5, 2026
Silence Therapeutics (SLN) continues to focus on advancing its RNA-based therapy pipeline while facing significant operating losses. The company reported a dramatic decline in revenue for FY 2025, dropping to $0.6…
10-Q · November 6, 2025
Silence Therapeutics PLC reported a significant decline in revenue for Q3 2025 with total revenue of $1.5 million, down from $1.3 million year-over-year. The company also saw a notable increase in operating loss, along…
10-Q · August 7, 2025
Silence Therapeutics PLC reported significant declines in revenue and EPS for Q2 2025, with actual revenues of $224,000 compared to estimates of $5.43 million. Gross profit was deeply negative at $2.58 million,…
This is our reading of a public filing, not the filing itself. Analysis can contain errors; check the source document for full context.